about image

MedicaSafe has been funded by the National Institutes of Health to curb medication misuse and to improve patient compliance.


Matt Ervin

Chief Executive Officer
Matt Ervin founded MedicaSafe after collaborating on NIH-funded projects to improve medication therapy management. Previously Matt founded Plum Voice, the leading independent SaaS platform for IVR, VoiceXML, and speech dialogs. Matt has 17 years of product management experience. He holds a B.A. from Harvard University in Physics and an M.S. from Harvard in Applied Sciences.

Thomas Lau

Chief Operating Officer
Tom’s 18 years of finance and operations experience include managing and launching a software business funded by Dow Jones and working as an investment executive at JP Morgan and Citigroup. He holds a B.A. from Yale University in Economics.

Colin Steel

Chief Technology Officer
Colin’s past work includes development of web applications and services for Pricewaterhousecoopers and JDM Interactive. He is an experienced instructor, having taught software design at CUNY Baruch for 15 years. He holds a B.A. in Computer Science from Columbia University.

Dr. Anand Mattai

Chief Medical Officer
Board certified in Psychiatry, Dr. Mattai pursued a clinical research fellowship at the National Institutes of Mental Health where he served as an investigator on several studies. He previously held positions as Medical Officer at the FDA Center for Drug Evaluation and Research and as Medical Director at Vanda Pharmaceuticals.
A summa cum laude graduate of Knox College and a graduate of the University of Iowa Carver College of Medicine, he completed his psychiatric residency at Creighton University/University of Nebraska College of Medicine.


Dr. Andrew Saxon

Advisory Board
Dr. Saxon has more than a quarter century of experience as a clinical and research addiction psychiatrist. Dr. Saxon is board certified with added qualifications in addiction psychiatry by the American Board of Psychiatry and Neurology. Dr. Saxon sits on the editorial boards of the journals, Drug and Alcohol Dependence and General Hospital Psychiatry and is section editor for substance use disorders for UpToDate. Dr. Saxon’s current research work is supported by the VA, the Department of Defense, and the National Institute on Drug Abuse and involves pharmacotherapies and psychotherapies for alcohol, cocaine, tobacco, and opioid use disorders as well work in co-occurrence of substance use disorders and posttraumatic stress disorder and on reducing homelessness.

Esther Dyson

Advisory Board
Esther Dyson is executive founder of the Way to Wellville, a ten-year, nonprofit evidence-generating project devoted to defining and refining models for investing in community health (not health *care*) that return profits to investors and health to the participants and their communities. Dyson is actively involved in overall policy and fundraising for Way to Wellville.
Esther invests in and nurtures start-ups, with a recent focus on health care (somewhat constrained to avoid conflicts with Wellville). On the health side, ​notable investments include 23andMe (also a director), Clover Health, ​MedicaSafe (advisory board), Nuna, Omada Health, PatientsLikeMe, Tocagen, Wellpass (director).

Dr. Zev Schuman-Olivier

Advisory Board
Dr. Zev Schuman-Olivier is Adjunct Assistant Professor of Psychiatry at Geisel School of Medicine at Dartmouth and Clinical Instructor of Psychiatry at Harvard Medical School. As a board-certified addiction psychiatrist, he has been involved with research and clinical care of patients with addiction and mental illness. He has conducted several research projects focusing on treatment of addictive disorders. Prior to his psychiatric residency, he helped coordinate and implement the first federally-funded, randomized controlled trial of a mindfulness-oriented intervention for addictive disorders. He was principal investigator on a NIDA grant to develop an ecological momentary assessment tool for investigating the effects of mindfulness training on smoking cessation. He also received a Harvard Medical School Dupont-Warren research fellowship to investigate the effects of meditation on inhibitory control. He has published numerous studies on the treatment of opioid dependence, addressing the challenges facing implementation of outpatient buprenorphine maintenance therapy.

Contact Us